Midlife Serum Cholesterol and Increased Risk of Alzheimer’s and Vascular Dementia Three Decades Later
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Aims: To investigate midlife cholesterol in relation to Alzheimer’s disease (AD) and vascular dementia (VaD) in a large multiethnic cohort of women and men. Methods: The Kaiser Permanente Northern California Medical Group (healthcare delivery organization) formed the database for this study. The 9,844 participants underwent detailed health evaluations during 1964–1973 at ages 40–45 years; they were still members of the health plan in 1994. AD and VaD were ascertained by medical records between 1 January 1994 and 1 June 2007. Cox proportional hazards models – adjusted for age, education, race/ethnic group, sex, midlife diabetes, hypertension, BMI and late-life stroke – were conducted. Results: In total, 469 participants had AD and 127 had VaD. With desirable cholesterol levels (<200 mg/dl) as a reference, hazard ratios (HR) and 95% CI for AD were 1.23 (0.97–1.55) and 1.57 (1.23–2.01) for borderline (200–239 mg/dl) and high cholesterol (≥240 mg/dl), respectively. HR and 95% CI for VaD were 1.50 (1.01–2.23) for borderline and 1.26 (0.82–1.96) for high cholesterol. Further analyses for AD (cholesterol quartiles, 1st quartile reference) indicated that cholesterol levels >220 mg/dl were a significant risk factor: HR were 1.31 (1.01–1.71; 3rd quartile, 221–248 mg/dl) and 1.58 (1.22–2.06; 4th quartile, 249–500 mg/dl). Conclusion: Midlife serum total cholesterol was associated with an increased risk of AD and VaD. Even moderately elevated cholesterol increased dementia risk. Dementia risk factors need to be addressed as early as midlife, before underlying disease(s) or symptoms appear.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Findings in late-life cohorts vary, with some finding higher levels of cholesterol associated with a lower risk356 and others finding a higher risk for VaD.357”
In the citing paper
“there are several controllable risk factors including obesity [156,157], hyperlipidemia [158,159], hypertension [160,161,162,163], type 2 diabetes [164,165,166,167], and sedentary lifestyle [168] that can be addressed in an effort to decrease the risk of developing AD.”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [158]
In the citing paper
“Obesity,71–73 dyslipidemia,74–77 and high BP78,79 are also major contributors to vascular brain health.”
From Defining Optimal Brain Health in Adults: A Presidential Advisory From the American Heart Association/American Stroke Association (2017) · cites this paper as [75]
Citations
Cites
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Hachinski, V., Iadecola, C., Petersen, R. C., Breteler, M. M., Nyenhuis, D. L., Black, S. E., Powers, W. J., DeCarli, C., Merino, J. G., Kalaria, R. N., et al. (2006) · Stroke · doi:10.1161/01.str.0000237236.88823.47 · Cited by 1,722 · cited 1×
“significantly increased the risk of developing VaD 3 decades later. High cholesterol levels (≥240 mg/dl) tended to increase VaD risk as well, but the association did not reach statistical significance. One reason for this could be the small sample size of VaD (127 persons in total, 39 with high cholesterol).VaD repres…”
BackgroundKrieger, N. (1992) · American Journal of Public Health · doi:10.2105/ajph.82.5.703 · Cited by 1,654 · cited 1×
“The present study investigates further the cholesterol-dementia relationship by focusing on the 2 main dementia subtypes, AD and vascular dementia (VaD), in a larger Kaiser Permanente cohort with updated follow-up information. We also examined the full range of cholesterol values (not just high cholesterol, >240 mg/dl…”
BackgroundMidlife cardiovascular risk factors and risk of dementia in late life
Whitmer, R. A., Sidney, S., Selby, J., Johnston, S. C., & Yaffe, K. (2005) · Neurology · doi:10.1212/01.wnl.0000149519.47454.f2 · Cited by 1,238 · cited 1×
“High midlife cholesterol has previously been shown to be a risk factor for dementia in the multiethnic cohort of women and men from the Kaiser Permanente Medical Care Program of Northern California [”
BackgroundSelf-citationKivipelto, M., Ngandu, T., Laatikainen, T., Winblad, B., Soininen, H., & Tuomilehto, J. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70537-3 · Cited by 1,126 · cited 1×
“Although our cohort does not include persons with mixed dementia as recognized by ICD-9 CM, the concomitant presence of neurodegenerative and vascular pathologies in a portion of the sample cannot be excluded. Clinical Significance and ConclusionsPhysicians tend to confine AD and VaD to geriatric age borders, and addr…”
ResultSelf-citationSerum Total Cholesterol, Apolipoprotein E {FC12}e4 Allele, and Alzheimer’s Disease
Notkola, I.-L., Sulkava, R., Pekkanen, J., Erkinjuntti, T., Ehnholm, C., Kivinen, P., Tuomilehto, J., & Nissinen, A. (1998) · Neuroepidemiology · doi:10.1159/000026149 · Cited by 669
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Iivonen, S., Mannermaa, A., Tuomilehto, J., Nissinen, A., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-3-200208060-00006 · Cited by 645
Self-citationIribarren, C., Sidney, S., Sternfeld, B., & Browner, W. S. (2000) · JAMA · doi:10.1001/jama.283.21.2810 · Cited by 482
Kalmijn, S., Foley, D., White, L., Burchfiel, C. M., Curb, J. D., Petrovitch, H., Ross, G. W., Havlik, R. J., & Launer, L. J. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.10.2255 · Cited by 417 · cited 1×
“but no association was observed in the Honolulu Asia Aging Study (HAAS) or Framingham study [”
BackgroundCrossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain
BJÖRKHEM, I. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01725.x · Cited by 381
Cited by
Items 101–200 of 553
Public Knowledge about Dementia in China: A National WeChat-Based Survey
Liu, D., Cheng, G., An, L., Gan, X.-G., Wu, Y., Zhang, B., Hu, S. H., Zeng, Y., & Wu, L. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16214231 · Cited by 82
“In reality, growing evidence suggests that obesity in midlife [44], diabetes [45,46], midlife hypertension [44,47], and midlife high cholesterol [48,49] are closely implicated as risk factors for dementia.”
BackgroundA Review of the Major Vascular Risk Factors Related to Alzheimer's Disease
Polidori, M. C., Pientka, L., & Mecocci, P. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120871 · Cited by 78
Robert, J., Stukas, S. K., Button, E. B., Cheng, W. H., Lee, M., Fan, J., Wilkinson, A., Kulić, I., Wright, S. D., & Wellington, C. L. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.10.005 · Cited by 98
Cholesterol-related genes in Alzheimer's disease
Wollmer, M. A. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.05.009 · Cited by 95
Cholesterol-enriched diet causes age-related macular degeneration-like pathology in rabbit retina
Dasari, B., Prasanthi, J. R. P., Marwarha, G., Singh, B. B., & Ghribi, O. (2011) · BMC Ophthalmology · doi:10.1186/1471-2415-11-22 · Cited by 82
Understanding the cause of sporadic Alzheimer’s disease
Zetterberg, H., & Mattsson, N. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.915740 · Cited by 73
“Vascular risk factors, such as hypertension, hyperhomocysteinemia and hypercholesterolemia, increase the risk of clinical AD [94–97].”
BackgroundCoronary risk correlates with cerebral amyloid deposition
Reed, B. R., Marchant, N. L., Jagust, W. J., DeCarli, C. C., Mack, W., & Chui, H. C. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.10.002 · Cited by 74
“Similarly, studies that measure lipids at midlife have consistently reported elevated late life risk of AD (Kivipelto et al., 2002; Kivipelto and Solomon, 2006; Solomon et al., 2009; Whitmer et al., 2005) whereas studies of late life hyperlipidemia report inconsistent or negative (protective) associations (Mielke et a…”
BackgroundRincón, F., & Wright, C. B. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32835c4f04 · Cited by 90
Williams, V. J., Leritz, E. C., Shepel, J., McGlinchey, R. E., Milberg, W., Rudolph, J. L., Lipsitz, L. A., & Salat, D. H. (2012) · Human Brain Mapping · doi:10.1002/hbm.22030 · Cited by 75
“…the risk for stroke and cerebrovascular disease, but it is also associated with increased incidence of cognitive decline [Breteler et al., 1994a; Solomon et al., 2009a; van Vliet et al., 2009], dementia [Dufouil et al., 2005; Stewart et al., 2007], and Alzheimer’s disease (AD) [Anstey et al.,…”
BackgroundInfluentialImfeld, P., Brauchli Pernus, Y. B., Jick, S. S., & Meier, C. R. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-121819 · Cited by 72
“Since certain cardiovascular co-morbidities such as hypertension [32], hypercholesterolemia [33], or diabetes mellitus [34] are discussed as potential risk factors for AD, our finding of a lower prevalence of these disorders in patients with AD (as compared to dementia-free controls) may come as a surprise.”
Schliep, K. C., Mclean, H., Yan, B., Qeadan, F., Theilen, L. H., de Havenon, A., Majersik, J. J., Østbye, T., Sharma, S., & Varner, M. W. (2023) · Hypertension · doi:10.1161/hypertensionaha.122.19399 · Cited by 69
Prasanthi, J. R. P., Schrag, M., Dasari, B., Marwarha, G., Dickson, A., Kirsch, W. M., & Ghribi, O. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111346 · Cited by 68
“Epidemiological studies have suggested that hypercholesterolemia is a risk factor for AD [28].”
Brooks, S. W., Dykes, A. C., & Schreurs, B. G. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160725 · Cited by 67
“Many studies have investigated the correlation between oxysterol levels and neurodegenerative disease but their findings are somewhat inconsistent [3, 22, 51–55].”
The shared role of cholesterol in neuronal and peripheral inflammation
Hansen, S. B., & Wang, H. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108486 · Cited by 73
Changes in Oxidative Damage, Inflammation and [NAD(H)] with Age in Cerebrospinal Fluid
Guest, J., Grant, R., Mori, T. A., & Croft, K. D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085335 · Cited by 66
“around 45–50 years) are associated with reduced cognitive function in later life [38–42].”
BackgroundInsulin resistance: a connecting link between Alzheimer's disease and metabolic disorder
Kshirsagar, V., Thingore, C., & Juvekar, A. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-020-00622-2 · Cited by 66
“2008), hypercholesterolemia (Solomon et al. 2009), hypertension (Nelson et al.”
Backgroundthe EPIDEMCA group, Guerchet, M., Mbelesso, P., Ndamba-Bandzouzi, B., Pilleron, S., Desormais, I., Lacroix, P., Aboyans, V., Jésus, P., Desport, J.-C., et al. (2014) · SpringerPlus · doi:10.1186/2193-1801-3-338 · Cited by 66
“…hypertension (Qiu et al. 2005; Kennelly et al. 2009), diabetes (Biessels et al. 2006; Profenno et al. 2010), midlife obesity (Barnes & Yaffe 2011), elevated midlife cholesterol (Solomon et al. 2009), physical inactivity (Hamer & Chida 2009) and smoking (Anstey et al. 2007; Peters et al. 2008).”
Alzheimer’s Disease, Cholesterol, and Statins: The Junctions of Important Metabolic Pathways
Silva, T., Teixeira, J., Remião, F., & Borges, F. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201204964 · Cited by 65
Sharma, S. (2021) · Physiology & Behavior · doi:10.1016/j.physbeh.2021.113528 · Cited by 74
Animal Models of Metabolic Disorders in the Study of Neurodegenerative Diseases: An Overview
Bem, A. F. D., Krolow, R., Farias, H. R., de Rezende, V. L., Gelain, D. P., Moreira, J. C. F., Duarte, J. M. N., & de Oliveira, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.604150 · Cited by 79
Physical activity, inflammation, and volume of the aging brain
Braskie, M. N., Boyle, C. P., Rajagopalan, P., Gutman, B. A., Toga, A. W., Raji, C. A., Tracy, R. P., Kuller, L. H., Becker, J. T., Lopez, O. L., et al. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.05.005 · Cited by 63
“Many of these effects relate to health factors that may modulate AD risk (Launer et al., 2000; Del Bo et al., 2009; Solomon et al., 2009; Lee et al., 2010; Matsuzaki et al., 2011; Piriz et al., 2011; Vargas et al., 2011; Crane et al., 2013; Tolppanen et al., 2013; Di Meco et al., 2014).”
Nutrition and vascular dementia
Perez, L., Helm, L., Sherzai, A., Jaceldo‐Siegl, K., & Sherzai, A. Z. (2012) · The journal of nutrition health & aging · doi:10.1007/s12603-012-0042-z · Cited by 70
“23), with desirable levels (<200 mg/dL) as the referent category (33).”
InfluentialHartin, P. J., Nugent, C. D., McClean, S. I., Cleland, I., Tschanz, J. T., Clark, C. J., & Norton, M. C. (2016) · JMIR mHealth and uHealth · doi:10.2196/mhealth.4878 · Cited by 64
“Numerous midlife health markers have been linked with higher late-life AD risk, such as obesity [18], hypertension [19], serum cholesterol levels [20], and physical activity during leisure time [21], all of which can be addressed simultaneously via a behavior change intervention to prevent the…”
Giugliano, R. P., Mach, F., Zavitz, K., Kurtz, C., Schneider, J., Wang, H., Keech, A., Pedersen, T. R., Sabatine, M. S., Sever, P. S., et al. (2017) · Clinical Cardiology · doi:10.1002/clc.22678 · Cited by 64
Transferrin and HFE genes interact in Alzheimer's disease risk: the Epistasis Project
Lehmann, D. J., Schuur, M., Warden, D. R., Hammond, N., Belbin, O., Kölsch, H., Lehmann, M. G., Wilcock, G. K., Brown, K. S., Kehoe, P. G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.07.018 · Cited by 68
“Risk factors for AD may act many years before disease nset, as with high blood pressure (Kivipelto et al., 2001; koog et al., 1996) and with high serum cholesterol Solomon et al., 2009).”
27-Hydroxycholesterol mediates negative effects of dietary cholesterol on cognition in mice
Heverin, M., Maioli, S., Pham, T. M., Mateos, L., Camporesi, E., Ali, Z., Winblad, B. G., Cedazo-Mínguez, Á., & Björkhem, I. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.10.018 · Cited by 71
New data on harmful effects of trans-fatty acids
Ginter, E., & Šimko, V. (2016) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2016_048 · Cited by 77
“A study of 444 Finnish men found that an elevated blood cholesterol level in midlife was associated with 3 times the risk of developing AD in late life (18).”
BackgroundHui, L., Chen, X., & Geiger, J. D. (2012) · Life Sciences · doi:10.1016/j.lfs.2012.04.039 · Cited by 58
“Moreover, independent of the ApoE gene, elevated levels of plasma cholesterol increase the risk of developing sporadic AD (Solomon et al., 2009).”
Effects of oxysterols on the blood–brain barrier: Implications for Alzheimer’s disease
Gosselet, F., Saint-Pol, J., & Fenart, L. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.11.059 · Cited by 53
“Furthermore, clinical and experimental studies have suggested that high levels of circulating cholesterol are closely linked to the onset and evolution of AD [18–23].”
BackgroundCalpain Dysregulation in Alzheimer’s Disease
Ferreira, A. (2012) · ISRN Biochemistry · doi:10.5402/2012/728571 · Cited by 62
“A population-based study demonstrated that not only high cholesterol levels but also moderately elevated cholesterol levels in midlife represent a significant risk factor for AD [106, 107].”
BackgroundPicard, C., Poirier, A., Bélanger, S., Labonté, A., Auld, D., Poirier, J., & on behalf of the PREVENT-AD Research Group (2019) · PLOS ONE · doi:10.1371/journal.pone.0220254 · Cited by 59
Structure of amyloid β25–35 in lipid environment and cholesterol-dependent membrane pore formation
Kandel, N., Matos, J. O., & Tatulian, S. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-38749-7 · Cited by 62
A New Hypothesis for Alzheimer’s Disease: The Lipid Invasion Model
Rudge, J. D. (2022) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-210299 · Cited by 58
Chronic Kidney Disease and Cognitive Impairment
Murtaza, A., & Dasgupta, I. (2020) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2020.105529 · Cited by 65
Ferguson, E. L., Zimmerman, S. C., Jiang, C., Choi, M., Swinnerton, K. N., Choudhary, V., Meyers, T. J., Hoffmann, T. J., Gilsanz, P., Oni‐Orisan, A., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207876 · Cited by 64
“9,44,45 Future studies with large diverse samples should investigate the association between trajectories in HDL-C and risk of dementia to give more context to our nonlinear fi nding.”
BackgroundResultInfluentialSelf-citationCholesterol, Statins, and Dementia: What the Cardiologist Should Know
Wanamaker, B. L., Swiger, K. J., Blumenthal, R. S., & Martin, S. S. (2015) · Clinical Cardiology · doi:10.1002/clc.22361 · Cited by 58
Olgiati, P., Politis, A. M., Papadimitriou, G. N., De Ronchi, D., & Serretti, A. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/832379 · Cited by 57
Prenatal high‐fat diet alters the cerebrovasculature and clearance of β‐amyloid in adult offspring
Hawkes, C. A., Gentleman, S. M., Nicoll, J. A., & Carare, R. O. (2015) · The Journal of Pathology · doi:10.1002/path.4468 · Cited by 54
Kuntz, M., Candela, P., Saint-Pol, J., Lamartinière, Y., Boucau, M.-C., Sevin, E., Fenart, L., & Gosselet, F. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150469 · Cited by 55
“A close relationship between cholesterol and AD is suggested by the fact that (1) cholesterol is a dietary risk factor in humans [3, 4] and animals [5–7] and (2) the ApoE4”
Prevention of Age-Related Cognitive Decline: Which Strategies, When, and forWhom?
Shatenstein, B., & Barberger-Gateau, P. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150256 · Cited by 52
“Metabolic factors such as obesity [97], particularly visceral obesity [98], the metabolic syndrome [99], high triglycerides [99, 100], high serum cholesterol, [101] low HDL-cholesterol [100], and diabetes [97, 102] are mainly associated with increased risk of cognitive decline or dementia when they are present at midd…”
BackgroundCerebral Perfusion Enhancing Interventions: A New Strategy for the Prevention of Alzheimer Dementia
de la Torre, J. C. (2016) · Brain Pathology · doi:10.1111/bpa.12405 · Cited by 63
“This thinking is supported by the presence of high levels of cholesterol, low density lipoprotein and triglycerides found in the blood of probable AD subjects (147).”
BackgroundDunk, M. M., Li, J., Liu, S., Casanova, R., Chen, J., Espeland, M. A., Hayden, K. M., Manson, J. E., Rapp, S. R., Shadyab, A. H., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13358 · Cited by 57
Clinical Application of APOE in Alzheimer's Prevention: A Precision Medicine Approach
Berkowitz, C. L., Mosconi, L., Rahman, A., Scheyer, O., Hristov, H., & Isaacson, R. (2018) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.35 · Cited by 58
“For example, one study evaluated the impact of midlife hyperlipidemia on the development of AD three decades later and showed that the hazard ratio for AD was 1.23 for borderline high cholesterol (200-239 mg/dl) and 1.57 for high cholesterol (≥ 240 mg/dl) (81).”
InfluentialStrand, B. H., Langballe, E. M., Hjellvik, V., Handal, M., Næss, Ø., Knudsen, G. P., Refsum, H., Tambs, K., Nafstad, P. H. J., Schirmer, H., et al. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.10.018 · Cited by 54
“The present results also support previous findings showing that high total serum cholesterol in middle age is associated with dementia in later life [11,16–19].”
ResultZarrouk, A., Hammouda, S., Ghzaiel, I., Hammami, S. O., Khamlaoui, W., Ahmed, S. H., Lizard, G., & Hammami, M. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666201203123046 · Cited by 53
Peters, R., Xu, Y., Antikainen, R., Beckett, N., Gussekloo, J., Jagger, C., Jukema, J. W., Keinanen-Kiukaanniemi, S., Rydén, L., Skoog, I., et al. (2021) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000519452 · Cited by 51
Vascular Risk Factors and Cognitive Decline in a Population Sample
Ganguli, M., Fu, B., Snitz, B. E., Unverzagt, F. W., Loewenstein, D., Hughes, T. F., & Chang, C.-C. H. (2013) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000004 · Cited by 56
Sacuiu, S. F. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802973-2.00008-2 · Cited by 73
Nasoohi, S., Parveen, K., & Ishrat, T. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180735 · Cited by 50
“Inthisline,smoking[16,17],obesity[18,19],hyperlipidemia[20, 21] and hypertension [22, 23] have been frequently addressed as risk factors for either cardiovascular dis-ordersorAD.”
Lamartinière, Y., Boucau, M.-C., Dehouck, L., Krohn, M., Pahnke, J., Candela, P., Gosselet, F., & Fenart, L. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170883 · Cited by 50
“Thus, the level of cholesterol in the blood can modify A (cid:2) peptide levels in the brain [6, 8, 9].”
Moreira, E. L. G., de Oliveira, J., Engel, D. F., Walz, R., Bem, A. F. D., Farina, M., & Prediger, R. D. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-1107-9 · Cited by 59
“Accumulating evidence over the past decade suggests that people with high serum cholesterol concentration in midlife have a significantly higher risk of Alzheimer’s disease (AD) in later life (Kivipelto et al. 2001, 2005; Alonso et al. 2009; Solomon et al. 2009; van Vliet et al. 2009; van Vliet 2012).”
BackgroundWang, C., Shou, Y., Pan, J., Du, Y., Liu, C., & Wang, H. (2019) · Nutritional Neuroscience · doi:10.1080/1028415x.2017.1416942 · Cited by 50
27-Hydroxycholesterol regulates cholesterol synthesis and transport in C6 glioma cells
An, Y., Zhang, D.-D., Yu, H., Ma, W., Lu, Y., Liu, Q.-R., & Xiao, R. (2017) · NeuroToxicology · doi:10.1016/j.neuro.2017.02.001 · Cited by 53
Rudajev, V., & Novotný, J. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01127-y · Cited by 54
Leoni, V., & Caccia, C. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.03.015 · Cited by 53
Jansen, D., Zerbi, V., Arnoldussen, I. A. C., Wiesmann, M., Rijpma, A., Fang, X. T., Dederen, P. J., Mutsaers, M. P. C., Broersen, L. M., Lütjohann, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075393 · Cited by 46
“other dementias [8–11].”
Fernández-de-Retana, S., Cano-Sarabia, M., Marazuela, P., Sánchez-Quesada, J. L., Garcia-Leon, A., Montañola, A., Montaner, J., Maspoch, D., & Hernández-Guillamon, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-15215-w · Cited by 49
LDL cholesterol is associated with higher AD neuropathology burden independent of APOE
Wingo, A. P., Vattathil, S. M., Liu, J., Fan, W., Cutler, D. J., Levey, A. I., Schneider, J. A., Bennett, D. A., & Wingo, T. S. (2022) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-328164 · Cited by 44
Lerner, A. J., Arnold, S. E., Maxfield, E., Koenig, A. M., Toth, M. E., Fortin, B. M., Mast, N., Trombetta, B. A., Denker, J. A., Pieper, A. A., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01151-z · Cited by 53
“modulates the processing of amyloid precursor protein into amyloid β (Aβ) peptides, a hallmark of AD [3–5], and multiple studies support the importance of cholesterol intake and serum cholesterol levels in AD [6, 7].”
BackgroundChronic administration of ellagic acid improved the cognition in middle-aged overweight men
Liu, Y., Yu, S., Wang, F., Yu, H., Li, X., Dong, W.-R., Lin, R., & Liu, Q. (2017) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2017-0583 · Cited by 47
Engel, D. F., de Oliveira, J., Lopes, J. B., Santos, D. B., Moreira, E. L. G., Farina, M., Rodrigues, A. L. S., de Souza Brocardo, P., & de Bem, A. F. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.05.029 · Cited by 44
Fernández-de Retana, S., Montañola, A., Marazuela, P., De La Cuesta, M., Batlle, A., Fatar, M., Grudzenski, S., Montaner, J., & Hernández-Guillamon, M. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.08.028 · Cited by 41
Effects of Dietary Food Components on Cognitive Functions in Older Adults
Ozawa, H., Miyazawa, T., & Miyazawa, T. (2021) · Nutrients · doi:10.3390/nu13082804 · Cited by 47
Endothelin-Converting Enzymes and Related Metalloproteases in Alzheimer's Disease
Pacheco-Quinto, J., Herdt, A., Eckman, C. B., & Eckman, E. A. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129043 · Cited by 43
“For some of these risk factors, the contribution appears at mid-life [89–92] before any pathological sign of AD, suggesting a direct effect on the initiation of the disease.”
The European Prevention of Alzheimer’s Dementia (EPAD) Consortium, Calvin, C. M., de Boer, C., Raymont, V., Gallacher, J., & Koychev, I. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00711-5 · Cited by 44
“Older age and the apolipoprotein e4 (APOE4) genotype are the leading constitutional risk factors for AD, yet modifiable vascular-related risk factors are associated with additional late-life risk of AD [24, 30, 37, 43], dementia risk [1, 12, 14, 34, 38, 41, 47] and AD pathology biomarkers in preclinical older-age indi…”
BackgroundXiao, Z., Wang, J., Chen, W., Wang, P., Zeng, H., & Chen, W. (2012) · Lipids in Health and Disease · doi:10.1186/1476-511x-11-163 · Cited by 41
“The recent identification has been extensively recognized that the effect of serum total cholesterol (TC) on dementia risk occurs in midlife but not late-life, which may be different cardiovascular risk factor profiles for AD [14,15].”
BackgroundRen, L., Bai, L., Wu, Y., Ni, J., Shi, M., Lu, H., Tu, J., Ning, X., Lei, P., & Wang, J. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00062 · Cited by 47
“Associations between conventional risk factors and cognition has not been conclusive (Knopman et al., 2001; Musen et al., 2008; Solomon et al., 2009).”
BackgroundZsido, R. G., Heinrich, M., Slavich, G. M., Beyer, F., Masouleh, S. K., Kratzsch, J., Raschpichler, M., Mueller, K., Scharrer, U., Löffler, M., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.6126 · Cited by 45
Chen, X., Wagener, J. F., Morgan, D. H., Hui, L., Ghribi, O., & Geiger, J. D. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101323 · Cited by 40
“All rights reserved the pathogenesis of sporadic AD [4–9], and rabbits fed cholesterol-enriched diets exhibit pathological features of AD [10–12].”
Downer, B. G., Zanjani, F. A. K., & Fardo, D. W. (2013) · Alcohol and Alcoholism · doi:10.1093/alcalc/agt144 · Cited by 44
“Elevated serum cholesterol during midlife is a risk factor for AD and vascular dementia (Solomon et al., 2009) and may contribute to the observed decline in learning and memory among moderate alcohol consumers who are APOE e4+ in the current study.”
BackgroundMethodGranic, A., & Potter, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060718 · Cited by 42
“patients [40–43,99,100].”
Chen, Y. L., Wang, L.-Y., Chen, Y., Gao, J. Y., Marshall, C., Cai, Z., Hu, G., & Xiao, M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.12.039 · Cited by 44
“Consistently, epidemiological investigations also show that elderly patients with hypercholesterolemia had an increased incidence of mild cognitive impairment, or even AD, when compared with the normal population (Pappolla et al., 2003; Solomon et al., 2009).”
Matton, A., Goikolea, J., Björkhem, I., Paternain, L., Kemppainen, N. M., Laatikainen, T. K., Ngandu, T., Rinne, J. O., Soininen, H. S., Cedazo-Mínguez, Á., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00790-y · Cited by 42
Self-citationSubramaniapillai, S., Suri, S., Barth, C., Maximov, I. I., Voldsbekk, I., van der Meer, D., Gurholt, T. P., Beck, D., Draganski, B., Andreassen, O. A., et al. (2022) · Human Brain Mapping · doi:10.1002/hbm.25882 · Cited by 47
Husain, I., Akhtar, M., Abdin, M. Z., Islamuddin, M., Yar, M. S., & Najmi, A. K. (2017) · Human & Experimental Toxicology · doi:10.1177/0960327117705431 · Cited by 39
“Moreover, it has been suggested that cholesterol fractions could be involved in both AD and vascular dementia.(52,53) It has been suggested that the useful effects of statins on neurodegeneration may not be only due to their cholesterol lowering effects, but also due to their cholesterol-independent or pleiotropic eff…”
BackgroundRegulation of Cerebral Cholesterol Metabolism in Alzheimer Disease
Reiss, A. B., & Voloshyna, I. (2012) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e318246d973 · Cited by 42
“A study that followed 9844 members of the Kaiser Permanente Northern California Medical Group ages 40 to 45 who had blood work done between 1964 and 1973 found that even borderline elevations in cholesterol (9 220 mg/dL) increased the risk of developing AD 3 decades later.(31) In contrast, The Prospective Population S…”
BackgroundInflammation as a Possible Link Between Dyslipidemia and Alzheimer’s Disease
Oliveira, B. C. D. L., Bellozi, P. M. Q., Reis, H. J., & de Oliveira, A. C. P. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.02.012 · Cited by 43
Association between statin use and Alzheimer’s disease with dose response relationship
Jeong, S., Shin, D. W., Yoo, T. G., Cho, M. H., Jang, W., Lee, J., & Kim, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-94803-3 · Cited by 40
Tan, J., Hu, M., Yang, Y., & Yang, Y. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.798334 · Cited by 66
“Studies reporting a significant association between high LDL-C level and AD risk are mostly studies where LDL-C concentration was measured in midlife (34, 35).”
BackgroundThe relationship between cholesterol and cognitive function is homocysteine-dependent
Gao, S., Cheng, Y., Jin, Y., Unverzagt, F. W., Su, L., Yang, L., Ma, F., Hake, A. M., Kettler, C. D., Chen, C., et al. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s64766 · Cited by 39
Long-term use of statins reduces the risk of hospitalization for dementia
Corrao, G., Ibrahim, B., Nicotra, F., Zambon, A., Merlino, L. G., Pasini, T. S., Catapano, A. L., & Mancia, G. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.07.009 · Cited by 37
Endocrine Risk Factors for Cognitive Impairment
Moon, J. H. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.2.185 · Cited by 41
Pro- and Anti-inflammatory Effects of High Cholesterol Diet on Aged Brain
Chen, Y., Yin, M., Cao, X., Hu, G., & Xiao, M. (2018) · Aging and Disease · doi:10.14336/ad.2017.0706 · Cited by 44
“A number of epidemiological studies have shown that hypercholesterolemia in midlife is related to an increased risk of developing AD or mild cognitive impairment in later life [8, 38].”
BackgroundBody mass index in early adulthood and dementia in late life: Findings from a pooled cohort
Zeki Al Hazzouri, A., Vittinghoff, E., Hoang, T., Golden, S. H., Fitzpatrick, A. L., Zhang, A., Grasset, L., & Yaffe, K. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12367 · Cited by 37
de Oliveira, J., Moreira, E. L. G., Mancini, G., Hort, M. A., Latini, A., Ribeiro‐do‐Valle, R. M., Farina, M., da Rocha, J. B. T., & Bem, A. F. D. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1110-4 · Cited by 36
“On the other hand, hypercholesterolemia, an early risk factor for AD [10, 13, 59], has been associated with brain oxidative stress [17, 60–62].”
Bransby, L., Rosenich, E., Maruff, P. T., & Lim, Y. Y. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.119 · Cited by 41
“Accordingly, midlife is considered the ideal age for modification of these MDRFs (10, 58).”
BackgroundMendoza‐Oliva, A., Zepeda, A., & Arias, C. (2014) · Current Alzheimer Research · doi:10.2174/1567205011666141001114858 · Cited by 39
Kotze, M. J., & van Rensburg, S. J. (2012) · Metabolic Brain Disease · doi:10.1007/s11011-012-9296-8 · Cited by 37
“Vascular risk factors such as high homocysteine levels may modify the neurodegenerative process in patients with mild cognitive impairment (MCI) at increased risk of VaD and AD.”
InfluentialLi, S., Geiger, N. H., Soliman, M. L., Hui, L., Geiger, J. D., & Chen, X. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142223 · Cited by 35
“…processing of A PP thus leading to increased AD (cid:1) internalization may decrease amyloidogenic process-ingofA (cid:1) PPandthusmightdecreaseADpathogenesis (LDL) cholesterol, independent of APOE genotypes is a robust extrinsic factor that increases the risk of developing sporadic AD [10–14].”
Use of a pooled cohort to impute cardiovascular disease risk factors across the adult life course
Hazzouri, A. Z. A., Vittinghoff, E., Zhang, Y., Pletcher, M. J., Moran, A. E., Bibbins-Domingo, K. B., Golden, S. H., & Yaffe, K. S. (2018) · International Journal of Epidemiology · doi:10.1093/ije/dyy264 · Cited by 37
ApoB, small-dense LDL-C, Lp(a), LpPLA 2 activity, and cognitive change
Pokharel, Y., Mouhanna, F., Nambi, V., Virani, S. S., Hoogeveen, R. C., Alonso, Á., HEISS, G. M., Coresh, J., Mosley, T. H., Gottesman, R. F., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007574 · Cited by 40
Xu, C., Apostolova, L. G., Oblak, A. L., & Gao, S. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191023 · Cited by 35
“Elevated serum total cholesterol in midlife [13] and in the elderly [14] is found to be associated with an increased risk of AD.”
Zhang, X., Geng, T., Li, N., Wu, L., Wang, Y., Zheng, D., Guo, B., & Wang, B. (2022) · Nutrients · doi:10.3390/nu15010069 · Cited by 37
“96) for midlife serum high cholesterol in the cohort study [8].”
BackgroundYi, L., Wu, T., Luo, W., Zhou, W., & Wu, J. (2014) · Neural Regeneration Research · doi:10.4103/1673-5374.125332 · Cited by 37
Are microRNAs the Molecular Link Between Metabolic Syndrome and Alzheimer’s Disease?
Codocedo, J. F., Ríos, J. A., Godoy, J. A., & Inestrosa, N. C. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9201-7 · Cited by 37
“On the other hand, clinical and epidemiological evidence indicates that the clusters of metabolic syndrome (MetS) such as hypertension [12], dyslipidemia [13], obesity [14], and T2DM [15] in a separate manner * Nibaldo C.”
BackgroundAssociations of Vascular Risk and Amyloid Burden with Subsequent Dementia
Gottesman, R. F., Wu, A., Coresh, J., Knopman, D. S., Jack, C. R., Rahmim, A., Sharrett, A. R., Spira, A. P., Wong, D. F., Wagenknecht, L. E., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26447 · Cited by 41
Engel, D. F., Grzyb, A. N., de Oliveira, J., Pötzsch, A., Walker, T. L., Brocardo, P. S., Kempermann, G., & de Bem, A. F. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.002 · Cited by 33
“Hypercholesterolemia is an important risk factor for the development of neurodegenerative diseases [1,2].”
BackgroundCho, Y., Han, K., Kim, D. H., Park, Y., Yoon, K., Kim, M. K., & Lee, S. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2020.935 · Cited by 33
“Associations between total cholesterol levels and the risk of dementia are controversial, and one study even showed that high total cholesterol level late in life is associated with a reduced risk of dementia [11-14].”
BackgroundCognitive memory screening and referral program in community pharmacies in the United States
Rickles, N. M., Skelton, J. B., Davis, J. L., & Hopson, J. (2013) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-013-9904-7 · Cited by 32
Incidence of dementia after age 90 in a multiracial cohort
Gilsanz, P., Corrada, M. M., Kawas, C. H., Mayeda, E. R., Glymour, M. M., Quesenberry, C. P., Lee, C., & Whitmer, R. A. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.12.006 · Cited by 35
Self-citation
Metadata
- Authors
- Solomon, A., Kivipelto, M., Wolozin, B., Zhou, J., & Whitmer, R. A.
- Affiliations
- University of Eastern Finland (FI)
- Boston University (US)
- Kaiser Permanente (US)
- Venue
- Dementia and Geriatric Cognitive Disorders
- Publisher
- S. Karger AG
- Published
- 2009
- Volume
- 28
- Issue
- 1
- Pages
- 75-80
- ISSN
- 1420-8008 (ISSN-L)
- 1421-9824
- PMC
- PMC2814023
- OpenAlex
- W2134458253
- Cited by
- 557
- References
- 22
- Citations by year
- 2026: 22 · 2025: 25 · 2024: 36 · 2023: 25 · 2022: 31 · 2021: 42 · 2020: 31 · 2019: 34 · 2018: 37 · 2017: 32 · 2016: 39 · 2015: 27 · 2014: 41 · 2013: 39 · 2012: 42
- FWCI
- 19.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Dementia and Geriatric Cognitive Disorders (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Kaiser Permanente
- National Institute of Diabetes and Digestive and Kidney Diseases (K01DK066308, DK066308)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, vascular dementia, dementia risk factors, total cholesterol, hypercholesterolemia, multi-ethnic cohort, men and women
- MeSH terms
- Adult, Aged, Alzheimer Disease, Cholesterol, Data Interpretation, Statistical, Female, Follow-Up Studies, Humans, Male, Middle Aged, Retrospective Studies, Socioeconomic Factors, Dementia, Vascular, Cohort Studies, Proportional Hazards Models, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.